What TOP MEDICINE does

Zhejiang Tuopu Pharmaceutical Co., Ltd., operating as TOP MEDICINE, is a Chinese pharmaceutical manufacturer founded in July 1999 and listed on the New Third Board (NEEQ: 837631) since June 2016. Headquartered in Deqing County, Zhejiang Province, the company operates a 59,050-square-meter integrated facility with GMP, US FDA (2007), Japan PMDA, and South Korea MFDS-certified API production lines. It manufactures pharmaceutical active ingredients, intermediates, veterinary drug raw materials, feed additives, and health food ingredients, supplying primarily B2B pharmaceutical manufacturers; secondary customers include cosmetic and personal care manufacturers purchasing arbutin and other whitening ingredients. The portfolio spans over 20 APIs (including diabetes SGLT2 inhibitors such as Canagliflozin/Dapagliflozin/Ertugliflozin, oncology agents like Palbociclib, and other therapeutics), chiral intermediates, and acylse enzyme products.

The company's core technical platform is enzyme-catalyzed green chemistry, a biocatalysis-based manufacturing approach positioned as an environmentally lower-impact alternative to traditional chemical synthesis. This platform underpins its 50% domestic market share in L-dihydrophenylglycine methyl Deng sodium salt (1,000-ton annual capacity) and supports a 15-patent portfolio, a provincial-level R&D center, and long-term collaborations with Fudan University, Shanghai Institute of Parasitology, Sichuan Antimicrobial Research Institute, and China Agricultural University. Workforce of 160 employees includes 3 PhDs, 4 senior engineers, and 69 professional/technical staff (45%+ of total).

Revenue mechanics are B2B direct sales with quote-based pricing on commodity-like intermediates and APIs—no disclosed pricing tiers, recurring contracts, or subscription model. Distribution is primarily direct to manufacturers, with international reach enabled by regulatory certifications rather than disclosed channel partnerships in the core pharma business. The company is investing in capacity expansion (a 105 million yuan technical renovation project for 300-ton orlistat chiral alcohol and 100-ton duloxetine chiral alcohol production, filed in 2024) and vertical extension into cosmetic ingredients (50-ton arbutin line launched in 2018). Growth signals are present but revenue scale, customer concentration, and explicit growth rates are not disclosed, reflecting the limited disclosure typical of NEEQ-listed small-cap Chinese manufacturers.

Name

TOP MEDICINE

Legal name

浙江拓普药业股份有限公司

Website

https://top-medicine.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Zhejiang Tuopu Pharmaceutical (TOP MEDICINE) is a China-based, NEEQ-listed manufacturer of pharmaceutical raw materials, intermediates, and cosmetic ingredients, serving drug and personal care manufacturers domestically and in FDA/PMDA/MFDS-certified export markets using enzyme-catalyzed green chemistry.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing (Active Pharmaceutical Ingredients and Intermediates)

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Chemicals & Allied Products (2800)

akta.pro primary industry

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

Keywords

• Pharmaceutical raw materials
• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Cosmetic raw materials
• Green chemistry manufacturing

Headquarters

HQ city

Deqing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Raw Materials and Intermediates: Manufactures and sells pharmaceutical raw materials, pharmaceutical intermediates, veterinary drug raw materials, feed additives, and health food products. Main products include L-dihydrophenylglycine methyl Deng sodium salt, furan ammonium salt, and polycarbophil calcium.
2. Cosmetic Raw Material Sales: Produces and sells cosmetic whitening ingredients including arbutin, targeting the beauty and personal care market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Zhejiang Tuopu Pharmaceutical Co., Ltd. (TOP MEDICINE) manufactures and sells pharmaceutical active pharmaceutical ingredients (APIs) such as amoxicillin, ampicillin, cephalosporin-class antibiotics, ribavirin, and atorvastatin calcium, along with pharmaceutical intermediates (e.g., D-phenylglycine methyl Deng sodium salt, D/L-4-hydroxyphenylglycine methyl Deng sodium salt), the Acylase enzyme used for chiral resolution, and cosmetic whitening raw materials (Arbutin). Production is based on proprietary enzyme catalysis (green chemistry) technology at a 59,050 m² facility in Deqing, Zhejiang.

Product overview

Zhejiang Tuopu Pharmaceutical Co., Ltd. (TOP MEDICINE) operates as a pharmaceutical manufacturer with a diversified product portfolio centered on Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, enzyme products (Acylase), and cosmetic whitening raw materials. The company produces over 20 pharmaceutical APIs including diabetes treatments (SGLT2 inhibitors like Canagliflozin, Dapagliflozin, Ertugliflozin), oncology drugs (Palbociclib, Ibrutinib), and other therapeutic agents. Their intermediate products support drug manufacturing for major pharmaceutical compounds. The company also manufactures Arbutin as a cosmetic whitening ingredient. Key products include L-dihydrophenylglycine methyl Deng sodium salt (annual capacity 1,000 tons, 50% domestic market share), along with fermentation and refining processes for various pharmaceutical compounds. The company operates under a CAPEX model for medical imaging deployments in Peru.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Active Pharmaceutical Ingredients (APIs) / 医药原料药 Bulk active pharmaceutical ingredients produced by TOP MEDICINE for sale to downstream drug manufacturers, including amoxicillin, ampicillin, cefradine, cefalexin, cefazolin sodium, ceftriaxone sodium, cefotaxime sodium, ceftazidime, cefepime, ribavirin, and atorvastatin calcium. Used as the active substance in finished antibiotic, antiviral, and cardiovascular drug formulations.
• Pharmaceutical Intermediates / 医药中间体 Chiral pharmaceutical intermediates produced via enzyme catalysis green chemistry, including D-phenylglycine methyl Deng sodium salt, D-4-hydroxyphenylglycine methyl Deng sodium salt, and L-4-hydroxyphenylglycine methyl Deng sodium salt. Sold to API manufacturers; the L-4-hydroxyphenylglycine methyl Deng sodium salt is the company's flagship intermediate with 50% domestic market share and 1,000 t/year capacity.
• Acylase Enzyme / 酰化酶 Industrial enzyme (Acylase) produced by TOP MEDICINE for sale as a biocatalyst used in chiral resolution and asymmetric synthesis to produce optically active pharmaceutical intermediates and APIs. Sold to pharma process developers and fine-chemical manufacturers.
• Cosmetic Whitening Raw Materials / 化妆品美白原料 (Arbutin / 熊果苷) Arbutin (熊果苷) whitening active ingredient produced by TOP MEDICINE and sold as a cosmetic-grade raw material to cosmetics and personal-care manufacturers for use in skin-whitening skincare formulations.
• Other Products and R&D Projects / 其它和在研项目

Quantifiable outcome

• 50% domestic market share for L-dihydrophenylglycine methyl Deng sodium salt
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and minor.

• Top Med SACcoreChannel Partner/ Reseller/ Distributor · 2 June 2026Nanox Imaging Ltd. announced an exclusive distribution agreement with Top Med SAC to deploy six Nanox.ARC medical imaging systems in Peru under a capex model. Top Med is responsible for obtaining regulatory approvals, marketing, installation, and ongoing technical support. This marks Nanox's entry into the Peruvian market.
• Shanghai Institute of Parasitology, Chinese Academy of Agricultural SciencescoreStrategic or Co-development PartnerLong-term development and cooperation with Chinese Academy of Agricultural Sciences Shanghai Institute of Parasitology for pharmaceutical research and development.
• Sichuan Antimicrobial Research InstitutecoreStrategic or Co-development PartnerLong-term R&D cooperation with Sichuan Antimicrobial Research Institute for pharmaceutical development and formulation research.
• Shanghai Fudan University Institute of MicrobiologycoreStrategic or Co-development PartnerLong-term development cooperation with Fudan University Institute of Microbiology for biotech and fermentation-based pharmaceutical research.
• China Agricultural University Institute of Applied ChemistrycoreStrategic or Co-development PartnerLong-term cooperation with China Agricultural University Institute of Applied Chemistry for chiral synthesis and pharmaceutical chemistry R&D.
• Zhejiang Biyang Environmental Engineering Technology Co., Ltd.minorImplementation/ SI/ Consulting PartnerCommissioned environmental impact assessment partner for production expansion projects including the 300-ton orlistat chiral alcohol and 100-ton duloxetine chiral alcohol technical renovation project, with total investment of 105 million yuan.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Regional players

• Zhejiang Garden Bio-Pharmaceutical (花园生物): Zhejiang-based specialty API manufacturer with similar provincial footprint, FDA/PMDA certifications, and vitamin D3/intermediates product mix. Comparable as a Zhejiang-region specialty API peer of similar scale.
• Zhejiang Xianju Pharmaceutical (仙琚制药): Zhejiang-based API and steroid hormone manufacturer with similar geographic footprint. Comparable as a Zhejiang-region API peer with mid-tier scale and similar China-centric distribution model.

Direct peers

• Zhejiang Huahai Pharmaceutical (华海药业): Major Chinese API manufacturer with strong US FDA-cleared portfolio and export focus. Comparable as a Chinese-based, internationally certified API/intermediates producer serving global pharma customers.
• Apeloa Pharmaceutical (普洛药业): Vertically integrated Chinese API and intermediates manufacturer with FDA/EMA certifications, producing APIs across multiple therapeutic categories. Comparable in scale, certification footprint, and product breadth to Top Medicine's API/intermediates franchise.
• Porton Pharma (博腾股份): Chinese CDMO focused on small-molecule APIs, intermediates, and chiral synthesis for global pharmaceutical customers. Comparable for its chiral chemistry capabilities and GMP/FDA-certified manufacturing.
• Shandong Xinhua Pharmaceutical (新华制药): Long-established Chinese API manufacturer producing a wide range of small-molecule APIs and intermediates for domestic and export markets. Comparable for multi-product API portfolio and regulatory certifications.
• Northeast Pharmaceutical Group (东北制药): State-affiliated Chinese API manufacturer with broad small-molecule API portfolio including intermediates and finished APIs. Comparable as a multi-product API manufacturer serving regulated markets.
• Asymchem Laboratories (凯莱英): Leading Chinese CDMO specializing in chiral synthesis, small-molecule APIs, and green chemistry manufacturing. Most direct comparable to Top Medicine's chiral chemistry focus (orlistat/duloxetine chiral alcohols) and enzyme catalysis manufacturing platform.

Broad incumbents

• Lonza Group: Global CDMO leader with deep capabilities in chiral chemistry, small-molecule APIs, and enzyme catalysis. Represents the scale benchmark Top Medicine's chiral platform is positioned against in international markets.
• WuXi AppTec / WuXi STA (药明康德): China's largest CRO/CDMO with full-spectrum API, intermediate, and formulation services including chiral synthesis. Operates at a much larger scale than Top Medicine but competes for similar small-molecule API/intermediates customers globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TOP MEDICINE